Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial.
By D. Kuter, J. Bussel, R. Lyons, V. Pullarkat, T. Gernsheimer, F. Senecal, L. Aledort, J. George, C. Kessler, M. Sanz and 22 more. The Lancet, 2008
846 citations recorded by the source corpus.
Subfields: Hematology, Surgery
View Paper: https://www.semanticscholar.org/paper/7343e8c9a2704aa4b529336eba37063b603c6568
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- D. Provan
- J. Bussel
- D. Cines
- R. Stasi
- F. Rodeghiero
- A. Newland
- T. Gernsheimer
- V. Blanchette
Citations in the corpus
- Updated international consensus report on the investigation and management of primary immune thrombocytopenia. (2019, neutral): “The average weekly romiplostim dose in most studies is 3 to 5 mg/kg, and $1 study has used 3 mg/kg as the initial dose.(113,131,139) Suboptimal platelet response may be improved by adding low doses (2.”
- American Society of Hematology 2019 guidelines for immune thrombocytopenia. (2019, neutral): “71,72 In a US analysis of primary trial results for each agent, 73,74 the total cost of eltrombopag was estimated at $66 560 and that of romiplostim at $91 039, inclusive of care for adverse and bleeding events over 26 weeks.”
- Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. (2009, neutral): “It varies depending on the mechanism of action of the specific agent (Table 3).(4,6-10,40-52) The frequency of monitoring of platelet counts and the timing of response assessment should be prespecified and will depend on the expected kinetics of platelet increase after each treatment.”
- International consensus report on the investigation and management of primary immune thrombocytopenia. (2010, background): “An overall platelet response rate (>4 out of 24 study weeks >50x10(9)/L) was observed in 79% and 88% of romiplostim-treated patients, compared with 0 and 14% in the respective placebo arms.(89) Similar results have been achieved with eltrombopag in chronic relapsed or refractory ITP patients (n=114)”